Recent developments, presentations, awards & more
-
19 September 2024
10th Steering Committee (SC) Meeting
The 10th GO-DS21 Steering Committee (SC) meeting takes place remotely on the 19th of September 2024 with the objective to prepare the upcoming project review meeting by the European Commission.
-
7 June 2024
Launch of “Let’s GO-DS21 video” and FOODFALL APP during the 5th T21RS conference.
We are pleased to introduce the GO-DS21 initiative aiming at understanding comorbidities in Down syndrome and suggest alternatives to reduce their consequences and improve the quality of life of individuals with Down syndrome, please have a look at our video “Let us GO-DS21”
In addition we would like to inform you of the launch of FOODFALL APP, an Educational game about healthy eating developed in collaboration with professionals from the Hospital del Mar, the Down Catalunya association and the support of GO-DS21 that helps people with Down syndrome. The app was launched during the 5th T21RS conference.
-
3 May 2024
GO-DS21 6th General Assembly Meeting
In one month from now, the 6th General Assembly meeting of the GO-DS21 will take place in the picturesque city of Rome from 2-4th of June 2024. Consortium partners will gather to discuss progress on the work since last meeting and give the chance to external advisors to provide their input in order to move the project forward.
-
8 March 2024
GO-DS21 Events before and on World Down Syndrome Day (WDSD) 2024
Patients and relatives, we are cordially inviting you to attend the following events during the coming weeks to celebrate and support World Down Syndrome Day 2024 (21 March because of 3 copies of chromosome 21 – hence month 3, day 21): The Association Française pour la Recherche sur la Trisomie 21 (AFRT) is organizing a French conference on “Aging Better with Down Syndrome” in Paris on Friday, 15 March (15:30 – 18:00 h) and Saturday, 16 March (9:00 – 17:30 h). In the United Kingdom, people and relatives affected by Down Syndrome are invited to come to The Francis Crick Institute in London on Saturday, 16 March, from 11:00 – 16:00 h. In Spain, the Parc de Recerca Biomèdica de Barcelona (PRBB) is hosting a fun and interactive event in Barcelona on Saturday, 16 March, starting at 10:30 h. Another event takes place at the Institut de Génétique, Biologie Moléculaire et Cellulaire (IGBMC) in Illkirch, France, on Thursday, 21 March, from 14:00 – 17:15 h. It is co-hosted by GO-DS21 coordinator Yann Hérault. Spread the news, help us overcome stereotypes, and post pictures and updates on social media about these events by using the hashtags #LotsOfSocks and #WorldDownSyndromeDay!
-
2 February 2024
GO-DS21 8th Steering Committee meeting
Mark your calendars for the upcoming GO-DS21 8th Steering Committee meeting, taking place in the picturesque city of London from 18th to 20th February 2024. We look forward to all work package progress reports and in-depth discussion within the committee.
-
10 September 2023
GO-DS21 5th General Assembly Meeting
The 5th General Assembly meeting of the GO-DS21 project took place in Paris from September 7th to 9th, 2023, and it was a fantastic success. We want to express our sincere thanks to all the consortium members and advisors who played a vital role in driving the GO-DS21 project forward with their invaluable contributions. Your commitment and hard work mean the world to us. Let’s keep up the great work and stay motivated as we achieve our goals!
-
9 September 2023
French event COMORBIDIT21 in Paris 2022
On 09 September 2023, we hosted the mostly French event COMORBIDIT21: “Improving knowledge about obesity and other comorbidities in Down Syndrome or Trisomy 21: The GO-DS21 network at the service of families and associations”.
-
7 September 2023
GO-DS21 5th General Assembly meeting
The GO-DS21 5th General Assembly meeting is going to take place on 7th-9th September 2023 in Paris.
-
26 April 2023
Tracking multiple morbidities across the lifespan in people with Down Syndrome
New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has explored the health experiences of people with Down Syndrome in an effort to better understand how the specific needs of people living with the condition compare to people with other forms of intellectual disability.
The report, published in the Lancet Public Health, is the first of its kind to research multiple morbidity across the lifespan in people with Down Syndrome. Researchers hope that this will help to ensure people living with the syndrome have access to the correct monitoring, support and treatment for health conditions at the right ages.
-
22 November 2022
DYRK1A, related kinases and human disease
Saint Malo, France, November 22-26, 2022 (President, organizer and speaker). (organized by Laurent MEIJER, Masatoshi HAGIWARA & Peter DE DEYN)
-
21 September 2022
GO-DS21 – A pan-European research project addressing common Down Syndrome comorbidities
Watch the GO-DS21 consortium members explain in this video an ambitious pan-European project that investigates the underlying mechanisms and etiology of common Down Syndrome (DS) comorbidities.
Clinicians, pathophysiologists, integrative bioinformaticians, and artificial intelligence computer scientists working to unravel intrinsic and extrinsic mechanisms that impact DS comorbidity (focusing on obesity and intellectual disability). The examination of the pathways and mechanisms involved in comorbidities and multi-morbidities that induce the coexistence of two or more diseases in an individual is of major importance for the effective treatment of patients suffering from DS, obesity, and mental disorders.
-
2 May 2022
GO-DS21 Clinical Trial video online
The new video about the GO-DS21 Clinical Trial in the Jerome Lejeune Institut is available on our #GODS21#youtubechannel now! Watch here:
-
29 April 2022
Meet the GO-DS21 Research Team
Researcher Chat this Friday at 3pm with the team from the UK GO-DS21. We’ll be joined by Prof. Andre Strydom, Prof. in Intellectual Disabilities @KingsCollegeLon and Dr. Li Chan, Reader in Molecular Endocrinology at Queen Mary University of London.
Let´s chat here (click on the link bellow)
-
9 February 2022
GO-DS21 3rd General Assembly meeting
The GO-DS21 3rd General Assembly meeting successfully took place on 8th-9th February 2022 via Zoom. Thank you to all consortium members and advisors that help bring the GO-DS21 project forward. Keep up the hard work!
-
2 February 2022
T21RS 4th International Conference, 9 – 12 June 2022
The 4th International Conference of the Trisomy 21 Research Society took place from June 9 to 12, 2022, in Long Beach, California.
The conference provided a platform for sharing the latest insights in basic, clinical, and translational research on Down syndrome.
-
9 December 2021
New video showing the benefits of our research
We are excited to share a video that our partner Institut Jérôme Lejeune has created. Please check out the video below to learn more about their work as well as how research can serve patients and their family. Versions with English and Spanish subtitles will also be available soon.
-
14 April 2021
ORE: Europe’s new open-access research platform has launched!
The European Commission has now officially launched “Open Research Europe” (ORE), the open access publishing platform for scientific articles presenting results of Horizon 2020 and future Horizon Europe projects. Let’s take advantage of this opportunity!
-
21 March 2021
Sunday, 21 March, is World Down Syndrome Day!
Join us on 21 March 2021 to actively advocate for the rights of people with Down syndrome! World Down Syndrome Day (WDSD), 21 March, is a global awareness day which has been officially observed by the United Nations since 2012. The date for WDSD being the 21st day of the 3rd month, was selected to signify the uniqueness of the triplication (trisomy) of the 21st chromosome which causes Down syndrome.
-
16 March 2021
Save the date – Brain Awareness Week Event on 16 March
The European Brain Council (EBC), the European Federation of Neurological Associations (EFNA), and GAMIAN-Europe are pleased to invite you to save the date for our upcoming Brain Awareness Week event on Patient Engagement in EU-Funded Brain Research Projects, to be held on 16 March 2021 from 12:30-14:00. This event looks to explore the current state of patient engagement in EU-funded brain research projects, looking at the Innovative Medicines Initiative (IMI) and MULTI-ACT as concrete examples and solutions. In discussion with key European Commission officials, we will discuss what has been done and what should be improved in order to guarantee change. Please save the date and keep an eye on your inbox – registration will launch soon! For more info click here.
-
1 August 2020
Down syndrome COVID-19 on-line survey
The “Trisomy 21 Research Society” (T21RS) is collecting vital information to understand the risks and course of COVID-19 among people with Down syndrome. The goal is to learn if people with Down syndrome are more vulnerable or have a different course of illness related to COVID-19 and if their illness is related to their pre-existing health profile. The survey is available in 5 European languages and can be filled out by carers/family mebers or clinicians.
-
1 June 2020
EDSA Coronavirus Special Page
GO-DS21 partner “European Down Syndrome Association” (EDSA) has created a Coronavirus Special Page where a list with helpful links to resources from organizations in various countries can be found: To Coronavirus Special Page.
-
27 May 2020
T21RS Covid-19 Survey
The COVID-19 Survey Report May 2020, of GO-DS21 partner “Trisomy 21 Research Society” (T21RS) is available for download here (PDF).
-
1 April 2020
T21RS recommendations
Our GO-DS21 partner “Trisomy 21 Research Society” (T21RS) has published some initial recommendations to protect individuals with Down syndrome against COVID-19: To T21RS recommendations.
-
5 February 2020
Welcome GO-DS21 Consortium and members of the scientific advisory board to the kick-off meeting in Strasbourg, France
GO-DS21 team will invest the next 5 years to help improve the lives of people with DS through the study of mechanisms driving DS comorbidities and the development of innovative clinical guidelines and therapies.